The United States Food and Drug Administration (US FDA) inspected Aurobindo Pharma's Unit VII, an oral manufacturing facility situated at Jedcherla, Hyderabad, from 2nd to 10th May 2022.

 At the end of the inspection, we have been issued a 'Form 483' with six observations. The Company will respond to the US FDA within the stipulated timeline and work closely with US FDA to close the observations, the company said in a statement.